We are live on ! Find out more
RGNX icon

Regenxbio

159 hedge funds and large institutions have $610M invested in Regenxbio in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 62 increasing their positions, 51 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more call options, than puts

Call options by funds: $4.47M | Put options by funds: $2.06M

22% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 51

1.14% less ownership

Funds ownership: 85.4%84.26% (-1.1%)

5% less funds holding

Funds holding: 167159 (-8)

18% less capital invested

Capital invested by funds: $742M → $610M (-$132M)

32% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 25

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
159
Holders Change
-8
Holders Change %
-4.79%
% of All Funds
2.52%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
17
Increased
62
Reduced
51
Closed
25
Calls
$4.47M
Puts
$2.06M
Net Calls
+$2.41M
Net Calls Change
-$136K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$132M -$4.39M -242,482 -3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$72M +$662K +36,531 +0.8%
JP Morgan Chase
3
JP Morgan Chase
New York
$60.3M -$656K -36,215 -1%
RG
4
Redmile Group
California
$42.4M +$9.92M +547,466 +27%
State Street
5
State Street
Massachusetts
$41.2M -$4.69M -258,635 -9%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$19.6M -$3.54M -195,442 -14%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$14.5M +$1.26M +69,617 +9%
ACM
8
Aquilo Capital Management
California
$13.9M -$411K -22,690 -3%
Balyasny Asset Management
9
Balyasny Asset Management
Illinois
$13M +$4.33M +238,677 +43%
Citadel Advisors
10
Citadel Advisors
Florida
$11.9M +$1.28M +70,765 +11%
MB
11
MPM BioImpact
Massachusetts
$10.8M
WM
12
WS Management
Florida
$10.2M -$3.22M -177,647 -22%
Goldman Sachs
13
Goldman Sachs
New York
$9.82M +$306K +16,875 +3%
First Manhattan
14
First Manhattan
New York
$9.61M +$625K +34,500 +6%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$9.26M +$27.1K +1,493 +0.3%
SGL
16
Sonic GP LLC
Hawaii
$8.53M -$4.08M -225,000 -30%
ECM
17
ExodusPoint Capital Management
New York
$8.17M +$107K +5,888 +1%
Northern Trust
18
Northern Trust
Illinois
$7.08M +$278K +15,356 +4%
Morgan Stanley
19
Morgan Stanley
New York
$6.29M +$65K +3,589 +0.9%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$5.94M -$113K -6,262 -2%
Charles Schwab
21
Charles Schwab
California
$5.36M +$500K +27,590 +9%
Norges Bank
22
Norges Bank
Norway
$4.46M
Ameriprise
23
Ameriprise
Minnesota
$4.27M -$107K -5,902 -2%
Principal Financial Group
24
Principal Financial Group
Iowa
$3.92M +$145K +7,977 +3%
Invesco
25
Invesco
Georgia
$3.84M -$183K -10,098 -4%

RGNX Hedge Fund Activity: Q3 2023 in Review

159 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2023, worth a combined $610M — down 18% from $742M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of RGNX and 17 opened new positions — a net loss of 8 holders — while 51 trimmed existing stakes and 62 added.

The largest buyer was Redmile Group, adding an estimated $9.92M. The largest seller was State Street, cutting an estimated $4.69M.

  • 159 institutional investors held Regenxbio (RGNX) as of Q3 2023, down from 167 in Q2 2023.
  • Funds reported $610M of Regenxbio stock for Q3 2023, down 18% quarter-over-quarter.
  • 17 funds opened new Regenxbio positions in Q3 2023 and 25 closed out, a net change of -8 holders.
  • The largest Regenxbio buyer in Q3 2023 was Redmile Group, an estimated $9.92M added.
  • The largest Regenxbio seller in Q3 2023 was State Street, an estimated $4.69M sold.

Based on aggregated 13F filings for Q3 2023.